Cancer Management and Research (Jul 2020)
Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review
Abstract
Zheng Yan,1 Zhi-Hua Yao,1 Shu-Na Yao,1 Qing-Xin Xia,2 Hai-Ying Wang,1 Jun-Feng Chu,1 Ming Song,1 Shuang Zhao,1 Yan-Yan Liu1 1Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of ChinaCorrespondence: Yan-Yan LiuDepartment of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, No. 127 Dongming Road, Zhengzhou, Henan 450008, People’s Republic of ChinaTel/ Fax +86 371-65587791Email [email protected]: Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.Keywords: primary mediastinal large B-cell lymphoma, immunotherapy, radiotherapy, nivolumab
